PKD is a kidney disorder in which cysts develop and enlarge in both kidneys, interfering with their ability to filter waste products from the blood, and eventually resulting in kidney failure. More than 12 Million people worldwide are affected by this insidious disease.
Autosomal dominant polycystic kidney disease (ADPKD) is one of two forms of Polycystic Kidney Disease, with many sufferers being diagnosed at between 30 and 50 years of age. Those afflicted with the disorder may go years without displaying symptoms. Once symptoms are presented, they may include back or stomach pain, blood in the urine, kidney stones, recurrent urinary infections and, ultimately, kidney failure.1
PKD is incurable, but—with treatment—symptoms can be managed and the progression of the disease may be reduced. Clinical trials play a critical role in potentially bringing new forms of treatment to light.
The chief purpose of this clinical trial is to determine the effect of an investigational medication—referred to as the “study drug” or “trial drug”—on the rate of total kidney volume (TKV) growth and the rate of renal function decline in patients at risk of rapidly progressive PKD. The efficacy, safety and tolerability of the trial drug will be measured against a placebo.
Patients who qualify to participate in this clinical trial may receive trial-related medication and medical care at no cost.